

Please fax both pages of completed form to your team at 808.650.6487.

To reach your team, call toll-free 808.650.6488.

You can now monitor shipments and chat online if you have questions. Go to MyAccredoPatients.com to log in or get started.

Prescription & Enrollment Form Lysosomal Storage Disorders (LSD)

accredo[®]
677 Ala Moana Blvd., Suite 404,
Honolulu, HI 96813-5412

Four simple steps to submit your referral.

1 Patient Information



Please provide copies of front and back of all medical and prescription insurance cards.

New patient Current patient

Patient's first name _____ Last name _____ Middle initial _____

Sex at birth: Male Female Preferred pronouns _____ Last 4 digits of SSN _____ Date of birth _____

Street address _____ Apt # _____

City _____ State _____ Zip _____

Home phone _____ Cell phone _____ E-mail address _____

Parent/guardian (if applicable) _____

Home phone _____ Cell phone _____ E-mail address _____

Alternate caregiver/contact _____

Home phone _____ Cell phone _____ E-mail address _____

OK to leave message with alternate caregiver/contact

Patient's primary language: English Other If other, please specify _____

2 Prescriber Information

All fields must be completed to expedite prescription fulfillment.

Date _____ Time _____ Date medication needed _____

Office/clinic/institution name _____

Prescriber info: Prescriber's first name _____ Last name _____

Prescriber's title _____ If NP or PA, under direction of Dr. _____

Office phone _____ Fax _____ NPI # _____ License # _____

Office contact and title _____ Office contact e-mail _____

Office street address _____ Suite # _____

City _____ State _____ Zip _____

Infusion location: Patient's home Prescriber's office Infusion site If infusion site, complete information below dotted line: _____

Infusion info: Infusion site name _____ Clinic/hospital affiliation _____

Site street address _____ Suite # _____

City _____ State _____ Zip _____

Infusion site contact _____ Phone _____ Fax _____ E-mail _____

3 Clinical Information

CHECK ONE

D84.1 Defects in the complement system E74.02 Pompe disease E75.21 Fabry disease E75.22 Gaucher disease
E75.240 Niemann-Pick disease type A E75.241 Niemann-Pick disease type B E75.242 Niemann-Pick disease type C
E75.244 Niemann-Pick disease type A/B E75.248 Other Niemann-Pick disease E75.249 Niemann-Pick disease, unspecified (NOS)
E75.5 Other lipid storage disorders E76.0 Mucopolysaccharidosis I (MPS I) E76.01 Hurler's Syndrome E76.1 Hunter Syndrome (MPS II)
E76.210 Morquio A syndrome (MPS IVA) E76.22 Sanfilippo mucopolysaccharidoses E76.29 Other mucopolysaccharidoses
E76.3 Mucopolysaccharidosis, unspecified **Other** _____

Other drugs used to treat the disease _____

Weight _____ kg/lbs Height _____ cm/in Date recorded _____

NKDA Known drug allergies _____

Concurrent meds _____

Adverse reactions with previous treatments? _____

If so, what therapy caused the reaction? _____

Patient's first name _____ Last name _____ Middle initial _____ Date of birth _____

Prescriber's first name _____ Last name _____ Phone _____

4 Prescribing Information

CHECK ONE

Medication				Directions	
ALDURAZYME® 2.9mg/5mL vial	FABRAZYME® 5mg or 35mg vial	MIGLUSTAT® 100mg capsule	XENPOZYME™ 20mg per vial**	Infuse _____ mg or _____ units intravenously every _____ week(s) OR Infuse _____ mg/kg or _____ units/kg. (where clinically appropriate, round to the nearest vial size) OR Take _____ tablet/capsules by mouth _____ times per day	Rate protocol: Titrate initial and maintenance infusions per manufacturer's product labeling. Vascular access: Peripheral Central Port Infusion method: Gravity Pump
CERDELGA® 84mg capsule	GALAFOLD® 123mg capsule	NAGLAZYME® 5mg/5mL vial			
CEREZYME® 400 unit vial	KANUMA® 20mg/10mL vial	NEXVIAZYME® 100mg vial			
ELAPRASE® 2mg/mL vial	LUMIZYME® 50mg vial	VIMIZIM® 1mg/mL vial			
ELELYSO® 200 unit vial	MEPSEVIL® 10mg/5mL vial	VPRIV® 400 unit vial			

*You must note the name of the brand product if brand is medically necessary for your patient _____

**Adult and pediatric titration dosing can be found in the Xenpozyme Package Insert _____

All medications requiring reconstitution and/or dilution will be prepared according to manufacturer guidelines.

Other instructions _____

Premedication to be given 30 minutes prior to infusion: (please check box to the left if desired to be included with order)

- Diphenhydramine 25mg by mouth for mild infusion reactions, may increase to 50mg for history of moderate to severe
- Acetaminophen 650mg by mouth
- MPS Patients: Cetirizine 10mg once a day unless prescribed on age (see below)
- Other _____

For patients weighing less than 60kg, the following weight-based dosing range will be used: Acetaminophen: 10–15mg/kg

For pediatric patients, the following weight- and age-based dosing range will be used:

- ≤9kg and/or <2 years old: Diphenhydramine 1mg/kg up to max of 6.25mg
- 2–5 years old and >9kg: Diphenhydramine 6.25mg to 12.5mg
- 6–12 years old: Diphenhydramine 12.5 to 25mg

MPS patients: Ceritizine: 2-6 years old 2.5mg once daily; adults and children >6 y/o 5mg once a day

Medications to be used as needed: (please check box to the left if desired to be included with order)

- Diphenhydramine 25mg by mouth every 4–6 hours as needed for mild infusion reactions, may increase to 50mg for moderate to severe; maximum of 4 doses per day
- Lidocaine 4% applied topically to insertion site prior to needle insertion as needed to prevent site pain
- Acetaminophen 650mg by mouth every 4–6 hours as needed for fever, headache or chills; maximum of 4 doses per day
- MPS patients: Ceritizine: 2-6 years old 2.5mg once daily; adults and children >6 y/o 5mg for mild symptoms and may use 10mg for severe symptoms

Adverse Reaction medications: (keep on hand at all times)

- Epinephrine 0.3mg auto-injector 2-pk for patients weighing greater than or equal to 30kg. Administer intramuscularly as needed for severe anaphylactic reaction times one dose
- Epinephrine 0.15mg auto-injector 2-pk for patients weighing less than 30kg. Administer intramuscularly as needed for severe anaphylactic reaction times one dose
- Diphenhydramine 25mg by mouth for mild allergic reactions and 50mg for moderate to severe
- Normal Saline 500mL bolus administered intravenously for allergic reaction/anaphylaxis, infuse wide open up to a max rate of 250mL per hour as tolerated by the patient (when required by manufacturer).

Flushing orders:

- 0.9% Normal Saline or Dextrose 5% (as required per manufacturer) 3mL intravenous (peripheral line) or 10mL intravenous (central line) before and after infusion, or as needed for line patency
- Heparin 10 units per mL 3mL intravenous (peripheral line) as needed for final flush
- Heparin 100 units per mL 5mL intravenous (central line) as needed for final flush
- Additional orders: may flush with 20mL Normal Saline post infusion to clear drug from line

Supplies: (please strike through if not required)

Dispense needles, syringes, ancillary supplies and home medical equipment necessary to administer medication.

Quantity/Refills: Dispense 1 month supply. Refill x 1 year unless noted otherwise. Dispense 90 day supply. Refill x 1 year unless noted otherwise.

Other _____

Skilled nursing visit as needed to establish venous access, administer medication and assess general status and response to therapy.

If shipped to physician's office or infusion clinic, physician accepts on behalf of patient for administration in office or infusion clinic.

Prescriber's signature required (sign below) (Physician attests this is his/her legal signature. NO STAMPS)

SIGN HERE

Date _____ Dispense as written _____ Date _____ Substitution allowed _____

The prescriber is to comply with his/her state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.



The document(s) accompanying this transmission may contain confidential health information that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party unless required to do so by law or regulation. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately and arrange for the return or destruction of these documents. All rights in the product names, trade names or logos of all third-party products that appear in this form, whether or not appearing with the trademark symbol, belong exclusively to their respective owners. © 2023 Accredo Health Group, Inc. | An Express Scripts Company. All rights reserved. IGL-00099-H-010423 CRP2204_0014888.1